Clinical trials
Observational Diabetes Mellitus, Type 2 trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
66 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 5 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 45 |
| Recruiting | 12 |
| Terminated | 5 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 16 |
| Boehringer Ingelheim | 6 |
| Bayer | 4 |
| Universitätsklinikum Hamburg-Eppendorf | 4 |
| AstraZeneca | 3 |
| German Diabetes Center | 3 |
| Diamontech AG | 2 |
| Eli Lilly and Company | 2 |
| GWT-TUD GmbH | 2 |
| Heinrich-Heine University, Duesseldorf | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 66 |
| Diabetes Mellitus | 20 |
| Diabetes Mellitus, Type 1 | 16 |
| Heart Failure | 7 |
| Insulin Resistance | 6 |
| Obesity | 5 |
| Anxiety Disorders | 4 |
| Arrhythmias, Cardiac | 3 |
| Asthma | 3 |
| Coronary Disease | 3 |
Trials
Showing 1 to 25 of 66. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.